Ketarx will be marketed in dosages including 10mg/ml, 50mg/ml, and 100mg/ml. Credit: Arek Socha from Pixabay.

PharmaTher and Vitruvias Therapeutics have entered a collaboration deal to commercialise PharmaTher’s Ketarx (racemic ketamine) in the US.

Ketarx will be marketed under the FDA-approved label of ketamine and in dosages that include 10mg/ml, 50mg/ml and 100mg/ml, with the option to boost the concentration and ready-to-administer applications.

Related Company Profiles

View all

Ketamine is currently on the FDA’s drug shortage list.

It is being given in hospitals and clinics for the treatment of mental health, neurological and pain disorders outside the FDA-approved indications.

PharmaTher plans to file an abbreviated new drug application with the FDA for Ketarx in July 2023, and to secure approval in the first quarter of 2024. Ketarx will then be commercially launched in the second quarter.

See Also:

The company and Vitruvias are planning pre-launch activities, including distribution, trade relations, pricing, marketing, and managed care and sales plans.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

PharmaTher CEO Fabio Chianelli stated: “Our highest priority is to obtain regulatory approvals and to commercialise Ketarx (racemic ketamine) worldwide for unmet medical needs.

“We are focused on building a network of strong commercial partnerships with leading speciality generic companies that are experienced in marketing, sales and distribution to the hospital, institutional and clinic channels within their territories.

“We are pleased to partner with Vitruvias for Ketarx for the US market and believe Vitruvias is the ideal partner to rapidly progress our commercialisation goals in the US and unlock new commercial opportunities internationally.”

This partnership with Vitruvias prepares the way for a definitive agreement under which PharmaTher will handle the regulation, production and supply of Ketarx.

Vitruvias would then undertake distribution, marketing and sales of Ketarx to hospital, institutional and clinic channels in the country.